61 Results

People

  1. Wolchok
    Wolchok
  2. Postow
    Postow
  3. Merghoub
    Merghoub
  4. Hellmann
    Hellmann
  5. Ricca
    Ricca
  6. Budhu
    Budhu
  7. Callahan
    Callahan
  8. Chan
    Chan
  9. Chapman
    Chapman
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (61)
  2. GSK Faculty (61)
  3. Melanoma and Immunotherapeutics Service (61)
  4. Solid Tumor Oncology Division (61)
  5. Melanoma Disease Management Team (24)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (15)
  7. Sloan Kettering Institute Postdocs (14)
  8. Human Oncology and Pathogenesis Program (12)
  9. Biostatistics Service (10)
  10. Epidemiology and Biostatistics (10)
  1. "2017"
  2. "Solid Tumor Oncology Division"
  3. "Jedd Wolchok"
Formats
  1. Journal Article (36)
  2. Meeting Abstract (24)
  3. Book Section (1)
Groups
  1. Department of Medicine (61)
  2. GSK Faculty (61)
  3. Melanoma and Immunotherapeutics Service (61)
  4. Solid Tumor Oncology Division (61)
  5. Melanoma Disease Management Team (24)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (15)

More Groups

People
  1. Jedd Wolchok (61)
  2. Michael Postow (20)
  3. Taha Merghoub (20)
  4. Matthew Hellmann (7)
  5. Jacob Ricca (6)
  6. Margaret Callahan (6)

More People

Years
  1. 2017 (61)
Publications
  1. Journal for ImmunoTherapy of Cancer (14)
  2. Journal of Clinical Oncology (7)
  3. Annals of Oncology (4)
  4. Nature (4)
  5. International Journal of Radiation Oncology, Biology, Physics (3)
  6. Lancet Oncology (3)

More Publications

Publishers
  1. Biomed Central Ltd (14)
  2. American Society of Clinical Oncology (7)
  3. Elsevier Inc. (7)
  4. Nature Publishing Group (6)
  5. Oxford University Press (5)
  6. American Association for Cancer Research (3)

More Publishers

Results (61)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Management of gastrointestinal (GI) toxicity associated with nivolumab (NIVO) plus ipilimumab (IPI) or IPI alone in phase II and III trials in advanced melanoma (MEL)
    Meeting Abstract

    Weber, J. S.; Larkin, J. M. G.; Schadendorf, D.; Wolchok, J. D.; Wagstaff, J.; Dummer, R.; Hogg, D.; Guidoboni, M.; Sosman, J. A.; Chmielowski, B.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Clinical benefit and toxicity of nivolumab plus ipilimumab in patients with advanced melanoma previously treated with checkpoint blockade inhibitors
    Meeting Abstract

    Friedman, C. F.; Wolchok, J. D.; Postow, M. A.; Shoushtari, A. N.; Callahan, M. K.; Momtaz, P.; Chapman, P. B.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Monotherapy dose escalation clinical and translational data from first-in-human study in advanced solid tumors of IPI-549, an oral, selective, PI3K-gamma inhibitor targeting tumor macrophages
    Meeting Abstract

    Hong, D.; Tolcher, A.; Sullivan, R.; Shapiro, G.; Chmielowski, B.; Ribas, A.; Brail, L.; Pearlberg, J.; Mahabhashyam, S.; Lee, L.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Targeting the IDO/TDO pathway through degradation of the immunosuppressive metabolite kynurenine and inhibition of the downstream AHR pathway
    Meeting Abstract

    McGovern, K.; Zhang, X. M.; Stone, E.; Triplett, T.; Garrison, K.; Coma, S.; Campesato, L. F.; Walsh, M.; Tchaicha, J.; Lamb, C.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Upregulation of PD-L1 in tumor microenvironment is a resistance mechanism for oncolytic virus immunotherapy
    Meeting Abstract

    Zamarin, D.; Ricca, J.; Oseledchyk, A.; Gigoux, M.; Merghoub, T.; Wolchok, J.
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Dissecting the mechanisms underlying antitumor effects of live oncolytic vaccinia and heat-inactivated vaccinia
    Meeting Abstract

    Wang, W.; Dai, P.; Yang, N.; Shuman, S.; Merghoub, T.; Wolchok, J.; Deng, L.
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • T cell immunotherapies trigger innate immunity and aseptic inflammation leading to potent anti-tumor and off-targets effects
    Meeting Abstract

    Hirschhorn, D.; Ricca, J.; Gasmi, B.; Mangarin, L. M.; De Henau, O.; Budhu, S.; Li, Y.; Cortez, C.; Xia, Y.; Zhong, H.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Isoform specific TGF-β inhibition in combination with radiation therapy as a novel immune therapeutic approach to cancer therapy
    Meeting Abstract

    Gupta, A.; Budhu, S.; Giese, R.; van Snick, J.; Uyttenhove, C.; Ritter, G.; Wolchok, J.; Merghoub, T.
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Phosphatidylserine targeting antibody in combination with tumor radiation and immune checkpoint blockade promotes anti-tumor activity in mouse B16 melanoma
    Meeting Abstract

    Budhu, S.; Giese, R.; De Henau, O.; Zappasodi, R.; Campesato, L. F.; Gupta, A.; Barker, C.; Freimark, B.; Wolchok, J. D.; Merghoub, T.
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Phase 1/1b, first-in-human study of the PI3K-gamma inhibitor IPI-549 as monotherapy and combined with nivolumab in patients with advanced solid tumors
    Meeting Abstract

    Ribas, A.; Hong, D.; Tolcher, A.; Sullivan, R.; Shapiro, G.; Chmielowski, B.; Brail, L.; Lee, L.; Mahabhashyam, S.; Ullmann, C. D.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save